Navigation Links
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Date:7/25/2008

of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborator, in connection with the development and commercialization of Genaera's IL-9 antibody program; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any
'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Stryker Orthopaedics, the Official Joint ... is rounding out its debut year of the relationship ... Scottsdale, AZ. This marks the eleventh tournament ... that the brand has activated on-site with the "Stryker ... fans on the importance of joint health.  ...
(Date:10/30/2014)... , Oct. 30, 2014  Zimmer Holdings, Inc. (NYSE: ... the future executive leadership team and organizational structure of ... transaction.  Zimmer also announced that the combined organization will ... be named Zimmer Biomet, with the new brand to ... closing of the merger.  The future leadership team is ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 2DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 3DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 4DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 5DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 6DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 7Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 2Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 3Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 4Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 5Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 6Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 7Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 8Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 9Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 10Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 11
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... 2014 PreDiabetes Centers , the ... shoppers with a supply of sugardown®, a chewable ... post-meal blood sugar spikes. Learning how to control blood ... part of a diabetes prevention plan. , Shoppers who ... complimentary tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... CT (PRWEB) October 30, 2014 Radio ... are raising questions about the impact of traditional radio ... marketing method most likely to influence a purchasing decision. ... poll of 525 consumers conducted by radio marketing company ... product categories, isolating the results of respondents who indicated ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
Breaking Medicine News(10 mins):Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3
... Treatment with the glitazone class of diabetes drugs leads ... macular edema (DME)a common complication that can lead to ... of the American Journal of Ophthalmology ( ... of about 170,000 patients with diabetes, Drs. Donald S. ...
... and David Glick highlight the serious issue of ... by F1000 Medicine Reports. , Consciousness during general ... post-operative psychological trauma and contributes towards patients, fear ... of 1000 Medicine and a leading authority on ...
... Be FeaturedSAN FRANCISCO, April 2 Over 1,000 cataract ... a San Francisco hotel Friday night. They will observe ... live from Key Whitman Eye Center in Dallas, Texas. ... approved accommodating Intraocular lens (IOL) in one patient and ...
... of Troy Limited (Nasdaq: HELE ), designer, ... household consumer products, today announced the March 31, 2009 ... global Infusium 23(R) hair care business from The Procter ... plus year heritage, has established a trusted reputation with ...
... Say They Will Not Provide Reimbursement for Xarelto ... Greater Convenience, According to a New Report from ... one of the world,s leading research and advisory ... for prevention of stroke, surveyed cardiologists estimate they ...
... is in the air, and along with it, tree, ... sufferer,s immune system a curve ball. But the April ... magazine uncovers five other surprising allergy ... need to be."When your immune system is weak, it ...
Cached Medicine News:Health News:Diabetes drug class linked to vision-threatening complication 2Health News:Surgeons to Observe and Discuss Live Eye Surgery Friday Night in San Francisco 2Health News:Surgeons to Observe and Discuss Live Eye Surgery Friday Night in San Francisco 3Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 2Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 3Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 4Health News:For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients 2Health News:For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients 3Health News:Surprising Allergy Triggers May Be Making Your Spring Sniffles Worse 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: